Skip to search formSkip to main contentSkip to account menu

sorafenib

Known as: 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, SFN 
A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (4)

Antineoplastic AgentsNiacinamidePhenylurea CompoundsProtein Kinase Inhibitors
NCIt Antineoplastic Agent TerminologySorafenib:MCnc:Pt:Ser/Plas:Qnanalogs & derivativessorafenib 200 MG Oral Tablet [Nexavar]

Narrower (1)

Nexavar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data
The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable… 
Review
2015
Review
2015
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Introduction: Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC). Alternative first- and second… 
Review
2013
Review
2013
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Highly Cited
2010
Highly Cited
2010
Pretreatment assessment of tumor enhancement on contrast‐enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving…
Tumor vascularity is a potential predictor of treatment outcomes in metastatic renal cell carcinoma (mRCC), and contrast… 
Highly Cited
2008
Highly Cited
2008
A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
Purpose: This study evaluated the safety, maximum tolerated dose, pharmacokinetics, and antitumor activity of sorafenib, a… 
Highly Cited
2008
Highly Cited
2008
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas
Medulloblastomas are the most frequent malignant brain tumors in children. Sorafenib (Nexavar, BAY43-9006), a multikinase… 
Review
2008
Review
2008
The role of microRNAs in primary liver cancer.
Highly Cited
2006
Highly Cited
2006
Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells
Mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) are activated in the majority of gliomas and contribute to… 
Highly Cited
2006
Highly Cited
2006
The second wave in kinase cancer drugs
Cancer drugs targeting signaling pathways have been hampered by problems of efficacy and tumor resistance. Will the next… 
Highly Cited
2003
Highly Cited
2003
Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytes.
The formation of DNA adducts in human HepG2 cells and human hepatocytes exposed to 14C-labelled 2-amino-1-methyl-6-phenylimidazo… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)